US EditionPublished • loading... • Updated
Aptose (APTOF) Spotlights Tuspetinib Triplet with 90% CR/CRh, 78% MRD-Negative AML
The TUS+VEN+AZA therapy achieved 100% complete remission at 80 mg and 120 mg doses, showing efficacy across diverse AML mutations with favorable safety, Aptose reported.
- On Dec. 06, 2025, Aptose Biosciences presented at the 67th ASH Annual Meeting that the TUS+VEN+AZA triplet achieved 100% CR/CRh at the 80 mg and 120 mg Tuspetinib cohorts and began the 160 mg dose with early responses.
- The TUSCANY Phase 1/2 study tests TUS combined with VEN and AZA to target newly diagnosed AML patients ineligible for induction chemotherapy and overcome venetoclax resistance.
- Early cohort results reveal 9 out of 10 evaluable patients responded, with MRD negativity at 78% by central flow cytometry and no dose-limiting toxicities across evaluable TUS dose levels.
- Clinical follow-up showed two subjects who underwent stem cell transplantation both returned for TUS maintenance, supporting TUS use across diverse AML populations including adverse mutation subgroups.
- Preliminary results at the 160 mg TUS dose cohort show early blast clearance and MRD-negativity, but formal responses were not included in poster data, and Aptose cautioned investors about forward-looking uncertainties.
Insights by Ground AI
13 Articles
13 Articles
Globe Newswire+10 Reposted by 10 other sources
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose’s Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population...
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutationsSafety continues to be a notable hallmark of TUS-based
·New York, United States
Read Full ArticleCoverage Details
Total News Sources13
Leaning Left8Leaning Right2Center2Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
C 17%
R 16%
Factuality
To view factuality data please Upgrade to Premium
